Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Generation and testing of clinical-grade exosomes for pancreatic cancer
Mayela Mendt, … , Valerie S. LeBleu, Raghu Kalluri
Mayela Mendt, … , Valerie S. LeBleu, Raghu Kalluri
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e99263. https://doi.org/10.1172/jci.insight.99263.
View: Text | PDF
Research Article Oncology

Generation and testing of clinical-grade exosomes for pancreatic cancer

  • Text
  • PDF
Abstract

Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.

Authors

Mayela Mendt, Sushrut Kamerkar, Hikaru Sugimoto, Kathleen M. McAndrews, Chia-Chin Wu, Mihai Gagea, Sujuan Yang, Elena V. Rodriges Blanko, Qian Peng, Xiaoyan Ma, Joseph R. Marszalek, Anirban Maitra, Cassian Yee, Katayoun Rezvani, Elizabeth Shpall, Valerie S. LeBleu, Raghu Kalluri

×

Figure 3

GMP-grade production of MSC-derived exosomes.

Options: View larger image (or click on image) Download as PowerPoint
GMP-grade production of MSC-derived exosomes.
(A) The number of exosomes...
(A) The number of exosomes, quantified by NanoSight, produced by 6 consecutive 48-hour isolations (harvests) of MSC-conditioned media from the bioreactor. (B) Particle size distribution analysis using NanoSight. (C) Correlation between the number of exosomes and exosomal protein from the bioreactor harvests (Pearson correlation test). Data shown in A–C are representative of the same data, obtained from the same bioreactor experiment (Bioreactor run 1) (see also Supplemental Figure 5A). (D) Representative TEM of exosomes from each of the 6 consecutive bioreactor harvests. Scale bar: 100 nm. (E) Representative histogram of flow cytometry analysis of exosomal markers (CD9, CD63, CD81) and CD47 on exosomes from bioreactor harvests 1 and 6 (see also Supplemental Figure 5D). Numbers represent the percentage of positive beads (gray, isotype control). See Supplemental Source Data 1 and 2.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts